Conference Coverage

Aspirin may protect against dementia in T2DM

 

Key clinical point: Long-term use of low-dose aspirin may protect against incident dementia in patients with type 2 diabetes mellitus.

Major finding: Daily low-dose aspirin reduced the incidence of dementia by more than one-third in patients with type 2 diabetes.

Study details: A multicenter randomized prospective cohort study of 2,536 patients with type 2 diabetes.

Disclosures: The study presenter reported having no financial conflicts.

Source: Matsumoto C. AHA scientific sessions.


 

REPORTING FROM THE AHA SCIENTIFIC SESSIONS

ANAHEIM, CALIF.Daily low-dose aspirin reduced the incidence of dementia by more than one-third in patients with type 2 diabetes mellitus in the randomized JPAD 2 study, Chisa Matsumoto, MD, reported at the American Heart Association scientific sessions.

The benefit was restricted to women with T2DM. During a median 9.7 years of follow-up, the incidence of dementia, as defined by prescription of antidementia drugs or hospitalization for dementia, was 2.7 cases per 1,000 person-years in women randomized to low-dose aspirin and 6 per 1,000 person-years in those assigned to standard care. This translated to a 60% relative risk reduction in a multivariate analysis adjusted for age, hypertension, dyslipidemia, smoking, and hemoglobin A1c level, according to Dr. Matsumoto of Hyogo (Japan) College of Medicine.

Dr. Chisa Matsumoto of Hyogo (Japan) College of Medicine Bruce Jancin/Frontline Medical News
Dr. Chisa Matsumoto
In men with T2DM, there was no significant difference in rates of new-onset dementia between the low-dose aspirin and control groups.

JPAD 2 was a multicenter prospective cohort study of 2,536 Japanese patients with T2DM who previously participated in the open-label randomized Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) trial, which ran from 2002 to 2008. Patients’ average age at baseline was 64 years; they had a 7-year duration of diabetes and no history of cardiovascular disease or dementia. When JPAD ended, patients continued on in JPAD 2, with follow-up through July 2015.

Next Article:

   Comments ()

Recommended for You

News & Commentary

Quizzes from MD-IQ

Research Summaries from ClinicalEdge